Agios Pharmaceuticals, Inc. (AGIO)
How AGIO actually reacts to news — the realized, point-in-time move the market made, measured across 492 labeled events over the last three years with zero look-ahead.
AGIO’s median reaction, across the day.
Half of all Agios Pharmaceuticals, Inc. news events land between -0.87% and +1.08% at 30 minutes.
Reaction stats as of 2026-08-18. Reaction = percent move vs. the price at the news timestamp.
Email me when AGIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AGIO’s baseline. Nothing else.
Get “How AGIO reacts to news” as a PDF.
A free one-page summary: AGIO’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent AGIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.19% | +0.66% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.04% | -2.67% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.82% | — | |
| Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.35% | +1.49% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +0.10% | |
| Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.02% | +0.69% | |
| Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -3.77% | -0.78% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.10% | -4.09% | |
| Agios Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +8.63% | +11.09% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.17% | -1.03% | |
| Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.17% | +2.81% | |
| Form 8-K AGIOS PHARMACEUTICALS, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +8.63% | +11.09% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.28% | -1.07% | |
| Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease | Press release | GlobeNewswire | +4.57% | +3.12% | |
| U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease | Press release | GlobeNewswire | +4.97% | +11.08% | |
| Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET | Press release | GlobeNewswire | +0.52% | +1.22% | |
| Form 8-K AGIOS PHARMACEUTICALS, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.45% | +2.33% | |
| Form S-8 AGIOS PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | +2.45% | +2.33% | |
| Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease | Press release | GlobeNewswire | -0.02% | +7.17% | |
| Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib | Press release | GlobeNewswire | -0.48% | -3.78% | |
| Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes | Press release | GlobeNewswire | +1.55% | +1.07% | |
| Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia | Press release | GlobeNewswire | +0.84% | -1.92% | |
| Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia | Press release | Business Wire | +0.02% | -1.92% | |
| Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease | Press release | GlobeNewswire | -1.53% | -0.20% | |
| Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias | Press release | GlobeNewswire | -0.92% | +0.42% | |
| Agios Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.11% | +5.85% | |
| Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.02% | +8.78% | |
| Form 8-K AGIOS PHARMACEUTICALS, For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | +5.85% | |
| Form ARS AGIOS PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.18% | -2.75% | |
| Form DEF 14A AGIOS PHARMACEUTICALS, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.18% | -2.75% | |
| Form DEFA14A AGIOS PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.18% | -2.75% | |
| Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET | Press release | GlobeNewswire | +0.00% | -1.86% | |
| Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA | Press release | GlobeNewswire | +1.57% | +0.33% | |
| Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates | Press release | GlobeNewswire | +1.81% | -2.01% | |
| Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.31% | +0.79% | |
| Form 10-K AGIOS PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.88% | +1.52% | |
| Form 8-K AGIOS PHARMACEUTICALS, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | +0.79% | |
| Form S-3ASR AGIOS PHARMACEUTICALS, | SEC filing · Form S-3ASR | SEC EDGAR | -0.30% | -2.51% | |
| Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET | Press release | GlobeNewswire | -0.81% | +1.98% | |
| Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth | Press release | GlobeNewswire | -0.89% | +0.78% | |
| Form 8-K AGIOS PHARMACEUTICALS, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | +0.78% | |
| Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 | Press release | GlobeNewswire | -0.34% | +1.25% | |
| U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia | Press release | GlobeNewswire | +1.27% | +4.18% | |
| Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia | Press release | GlobeNewswire | +0.04% | -1.16% | |
| Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease | Press release | GlobeNewswire | -0.69% | -3.54% | |
| Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition | Press release | GlobeNewswire | +1.93% | -6.37% | |
| Agios Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.70% | +2.37% | |
| Form 10-Q AGIOS PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.30% | +0.09% | |
| Form 8-K AGIOS PHARMACEUTICALS, For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | -2.70% | +2.37% | |
| Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia | Press release | GlobeNewswire | +1.60% | +0.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AGIO section they belong to.
More of the dataset.
AGIO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Agios Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled AGIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 492 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of AGIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-18.
Does AGIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.